There’s a new way to screen for early detection of Alzheimer’s disease. On Friday, the Food and Drug Administration (FDA) cleared the first blood test for the disorder. Fujirebio Diagnostics’ Lumipulse measures the ratio of two proteins that correlate with the presence or absence of Alzheimer’s. Previously, patients being screened for Alzheimer’s were limited to more invasive options: a PET Scan or spinal tap.
Lumipulse is intended for use in clinical settings with patients exhibiting signs of cognitive decline. At least in its current form, it isn’t something the general population can ask for as a standard screening.
The test works by measuring
→ Continue reading at Engadget
